ASP3082/Targeted Protein Degradation Online Meeting

from the beginning

TARGETED PROTEIN DEGRADATION

TARGETED PROTEIN DEGRADATION

• Cautionary statement regarding forward-looking information

• Contents

INTRODUCTION

• Targeted protein degraders have the potential to overcome limitations of traditional small molecules and tackle “undruggable” targets

TARGETED PROTEIN DEGRADATION STRATEGY

• We aspire to evolve TPD into a key capability for Astellas and a major driver of our pipeline expansion

• Mutated KRAS is a historically “undruggable” target and KRAS G12D is the most common KRAS driver mutation

• There is high unmet need in cancers expressing KRAS G12D mutations - take PDAC as an example

PROGRESS ON ASP3082

• Our lead program, ASP3082, is the first protein degrader for mutated KRAS G12D to enter the clinic

• Phase 1 study design of ASP3082

• Our Phase 1 study population primarily had advanced pancreatic, colorectal and non-small cell lung cancer

• ASP3082 safety profile in doses up to 600mg

• ASP3082 exceeded target exposure in the body >300mg QW and KRAS G12D was degraded in a dose-dependent manner

• Antitumor activity was observed in patients with PDAC and NSCLC receiving doses between 300-600mg

• Responses to ASP3082 over time in patients with PDAC and NSCLC

• The results and safety profile of ASP3082 support further clinical investigation

PIPELINE UPDATE

• Robust early research pipeline leveraging advantages of protein degraders

• Our portfolio consists of targeted protein degraders-addressing historical “undruggables”

• Our in-house expertise further advances this complex modality

• Collaboration with external partners - acquiring novel POI/E3 binders to develop innovative targeted protein degraders

@

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8